The Australian Early Phase Biosimilars Clinical Trial Landscape - How Agilex Biolabs and Nucleus Network Work Together
In this webinar you will hear from Agilex Biolabs and Phase 1 contract research organisation Nucleus Network about how they work together to deliver clinical research outcomes in biosimilars.
Agilex Biolabs is the leading bioanalytical laboratory in biosimilars in Asia Pacific with several platforms for sensitive technology, including Gyrolab, to develop state-of-the art assays. Agilex Biolabs has supported numerous biosimilar studies conducted across Australia, Asia Pacific and Europe for phase 1 and phase 3 generic antibody/peptide therapeutics; including Teriparatide, Bevacizumab, Trastuzumab, Omalizumab and Eculizumab. Our scientists have a breadth of knowledge and experience in ligand binding assays, antidrug-antibody assays and neutralising antibody assays with in-depth expertise in troubleshooting immunogenicity assays, which can be challenging to develop, to meet the high drug and target tolerance required for later phase studies.
Nucleus Network is a leading Phase 1 clinical research organisation with three specialised clinical units: two in Australia and one in the US. Nucleus Network works closely with Agilex Biolabs and its clients, and this this long-standing relationship delivers significant advantages to biotechs wanting a streamlined and collaborative approach to their early phase biosimilars studies.
